OUTSOURCING
The Top 10 Contract Research
Organizations
Positioning, performance and SWOT analyses
ii
Copyright © 2009 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd. The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.
While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.
iii
Table of Contents
The Top 10 Contract Research Organizations
Executive summary
14
Industry overview 14
Quintiles 15
Covance 15
Pharmaceutical Product Development (PPD) 16 Charles River Laboratories (CRL) 16
ICON Clinical (ICON) 17
Parexel 17
MDS 18
Kendle 18
PharmaNet Development (PharmaNet) 19
PRA International 19
Chapter 1
Introduction 22
What is this report about? 22 Methodology 22
Chapter 2
Industry overview
24
Summary 24
Introduction 25
Market overview 25
Global CRO market: size and growth 25
Global positioning of the top 10 CROs 26
Key market drivers 29
Key market resistors 30
iv
Full-services CROs 31
Niche CROs 31
Trends in the global CRO industry 32
Consolidation in the CRO industry 32
Evolution of software as a service (SaaS) based electronic data capture (EDC) 35
Implementation of biomarkers in clinical trials 36
Participation of private equity players 38
New CRO destinations 39
Asia-Pacific 39
India 39 China 40
Latin America 42
Eastern Europe 42
Africa 43
Chapter 3
Quintiles 46
Summary 46
Company overview 47
Recent financial performance 48
Growth strategies 48
Investing in infrastructure 48
Expansion of consulting business 50
Acquisitions and divestments 50
SWOT analysis 51
Strengths 52
Depth in service offerings 52
Strong presence in emerging economies 52
Weaknesses 53
Exposure in limited therapeutic areas 53
Opportunities 53
Launch of interactive data analysis tool 53
New facility in India 53
Expansion in Japan 53
Threats 54
Stringent regulations 54
Increasing competition 55
Chapter 4
Covance 58
Summary 58
Company overview 59
v
Performance by business segment 61
Growth strategies 61
Attaining operational efficiency through six sigma implementation 61
Develop capabilities in emerging markets 62
Acquisitions and divestments 62
SWOT analysis 63
Strengths 63
Global capabilities 63
Stronger therapeutic base 64
Strong liquidity position 64
Weaknesses 64
Declining performance in late-stage segment 64
Opportunities 65
Expanding facilities in mature pharmaceutical markets 65
R&D collaboration with Eli Lilly 65
Threats 66
Weakening early-stage development segment 66
Regulatory compliance 66
Chapter 5
Pharmaceutical Product
Development 68
Summary 68
Company overview 69
Recent financial performance 69
Performance by business segment 70
Growth strategies 71
Collaboration for development of innovative compounds 71
Expansion in central laboratory services 71
Acquisitions and divestments 72
SWOT analysis 73
Strengths 74
Depth in phase II–IV service offering 74
Strong financial performance 74
Weaknesses 74
Declining revenue contribution from PPD’s discovery segment 74
Opportunities 75
Investment in technologies 75
Geographical expansion 75
Outsourcing deal with Merck 76
Threats 76
vi
Chapter 6
Charles River Laboratories
78
Summary 78
Company overview 79
Recent financial performance 79
Performance by business segment 80
Growth strategies 81
Building capabilities for clients 81
Acquisitions and divestments 81
SWOT analysis 82
Strengths 83
Strong technology platforms for pre-clinical testing 83
Weaknesses 83
Higher debt burden 83
Opportunities 84
Expansion in China 84
Threats 84
Cost cutting in biopharmaceutical industry 84
Chapter 7
ICON 86
Summary 86
Company overview 87
Recent financial performance 87
Performance by business segments 88
Growth strategies 88
Developing global capabilities and reach 88
Acquisitions and divestments 89
SWOT analysis 90
Strengths 90
Strong presence in oncology solutions 90
Technically enhanced service offerings 91
Unconventional service model 91
Weaknesses 92
Rising debt load 92
Opportunities 92
Expansion in India 92
Agreement with Phase Forward 92
Threats 93
Government regulations 93
vii
Chapter 8
Parexel 96
Summary 96
Company overview 97
Recent financial performance 97
Performance by business segments 98
Growth strategies 99
Expansion in emerging markets 99
Acquisitions and divestments 100
SWOT analysis 101
Strengths 101
Strong global presence 101
Stronger therapeutic presence 102
Weaknesses 102
Increased receivable turnover period 102
Opportunities 102
Expansion in early-phase service offerings 102
Threats 103
Consolidation in the industry 103
Declining R&D spending growth 103
Chapter 9
MDS 106
Summary 106
Company overview 107
Recent financial performance 107
Performance by business segment 109
Growth strategies 109
Internal restructuring 109
Investment in infrastructure across geographies 110
Acquisitions and divestments 110
SWOT analysis 111
Strengths 111
Robust performance of late-stage contract research services 111
Weaknesses 112
Limited therapeutic focus 112
Opportunities 112
Investment in technology 112
Expansion in Asian markets 113
Threats 113
viii
Chapter 10
Kendle 116
Summary 116
Company overview 117
Recent financial performance 117
Performance by business segment 119
Growth strategies 119
Participation in mega-trials 119
Acquisitions and divestments 120
SWOT analysis 121
Strengths 121
Strong presence in phase I–IV clinical services 121
Growth in operating profit 122
Broader therapeutic exposure 122
Weaknesses 123
Rising debt burden 123
Opportunities 123
Growth in the early-stage research segment 123
Expansion in Asia-Pacific 124
Threats 124
Highly competitive environment 124
Chapter 11
PharmaNet 126
Summary 126
Company overview 127
Recent financial performance 127
Performance by business segments 129
Growth strategies 129
Global expansion of capacity 129
Early-stage expansion 129
Late-stage expansion 130
Investment in technology 130
Acquisitions and divestments 130
SWOT analysis 131
Strengths 131
Extensive services spectrum 131
Diverse client base across geographies 132
Weaknesses 133
Late-stage project cancellations 133
Opportunities 133
Investing in laboratory capabilities to analyze complex molecules 133
Threats 133
ix
Refinancing convertible debt 134
Government regulations 134
Chapter 12
PRA International
136
Summary 136
Company overview 137
Recent financial performance 137
Growth strategies 138
Capacity expansion across geographies 138
Increased prominence in oncology 139
Acquisitions and divestments 139
SWOT analysis 140
Strengths 140
Services portfolio 140
Weaknesses 141
Limited therapeutic expertise 141
Lower sales growth during 2004–07 141
Opportunities 141
Collaboration with Frontage Laboratories 141
Growing opportunities in India 142
Threats 142
Intense competition 142
Regulatory compliance 143
Chapter 13
Other key players
146
Aptuit 146
Company overview 146
Recent financial performance 146
Life Sciences Research 147
Company overview 147
Recent financial performance 147
Omnicare 149
Company overview 149
Recent financial performance 149
SGS 151
Company overview 151
Recent financial performance 151
CMIC 153
Company overview 153
Recent financial performance 153
x
Company overview 155
Recent financial performance 155
Galapagos (BioFocus) 157
Company overview 157
Recent financial performance 157
LAB Research 159
Company overview 159
Recent financial performance 159
United BioSource 161
Company overview 161
Recent financial performance 161
Bio-Imaging 162
Company overview 162
Recent financial performance 162
Chapter 14
Appendix 166
Glossary 166
Index 168
List of Figures
Figure 2.1: Global CRO market size ($bn), 2008–13 26
Figure 2.2: Top 10 CRO companies market share (%), 2007 27
Figure 2.3: Market position of the global top 10 CROs, 2007 28
Figure 2.4: Comparative analysis of leading CRO companies 29
Figure 2.5: Comparison between India and China CROs 41
Figure 3.6: Quintiles SWOT analysis 51
Figure 4.7: Covance financial performance ($m), 2003–07 60
Figure 4.8: Covance SWOT analysis 63
Figure 5.9: PPD financial performance ($m), 2003–07 70
Figure 5.10: PPD SWOT analysis 73
Figure 6.11: CRL financial performance ($m), 2004–07 80
Figure 6.12: CRL SWOT analysis 82
Figure 7.13: ICON SWOT analysis 90
Figure 8.14: Parexel financial performance ($m), 2004–08 98
Figure 8.15: Parexel SWOT analysis 101
Figure 9.16: MDS financial performance ($m), 2005–07 108
Figure 9.17: MDS SWOT analysis 111
Figure 10.18: Kendle financial performance ($m), 2003–07 118
Figure 10.19: Kendle SWOT analysis 121
Figure 11.20: PharmaNet financial performance ($m), 2004–07 128
Figure 11.21: PharmaNet SWOT analysis 131
xi
Figure 12.23: PRA International SWOT analysis 140
Figure 13.24: LSR financial performance ($m), 2003–07 148
Figure 13.25: Omnicare financial performance ($m), 2003–07 150
Figure 13.26: SGS financial performance ($m), 2003–07 152
Figure 13.27: CMIC financial performance ($m), 2005–08 154
Figure 13.28: WuXi Pharmatech financial performance ($m), 2003–07 156
Figure 13.29: BioFocus financial performance ($m), 2005–07 158
Figure 13.30: Lab Research financial performance ($m), 2005–07 160
Figure 13.31: Bio-Imaging financial performance ($m), 2003–07 163
List of Tables
Table 2.1: Global CRO market size ($bn), 2008–13 26
Table 2.2: Select M&A deals in CRO industry 2007–08 32
Table 2.3: Select private equity deals in CRO industry ($m), 2007–08 38
Table 3.4: Quintiles snapshot 46
Table 3.5: Quintiles financial performance ($m), 2003–07 48
Table 4.6: Covance snapshot 58
Table 4.7: Covance financial performance ($m), 2003–07 59
Table 4.8: Covance business segment performance, 2007 61
Table 5.9: PPD snapshot 68
Table 5.10: PPD financial performance ($m), 2003–07 69
Table 5.11: PPD business segment performance, 2007 70
Table 6.12: CRL snapshot 78
Table 6.13: CRL financial performance ($m), 2004–07 79
Table 6.14: CRL business segment performance, 2007 80
Table 7.15: ICON snapshot 86
Table 7.16: ICON financial performance ($m), 2003–07 87
Table 7.17: ICON business segment performance, 2007 88
Table 8.18: Parexel snapshot 96
Table 8.19: Parexel financial performance ($m), 2004–08 97
Table 8.20: Parexel business segment performance, 2008 99
Table 9.21: MDS snapshot 106
Table 9.22: MDS financial performance ($m), 2005–07 108
Table 9.23: MDS business segment performance, 2007 109
Table 10.24: Kendle snapshot 116
Table 10.25: Kendle financial performance ($m), 2003–07 117
Table 10.26: Kendle business segment performance, 2007 119
Table 11.27: PharmaNet snapshot 126
Table 11.28: PharmaNet financial performance ($m), 2004–07 128
Table 11.29: PharmaNet business segment performance, 2007 129
Table 12.30: PRA International snapshot 136
Table 12.31: PRA International financial performance ($m), 2003–07 137
Table 13.32: Aptuit Snapshot 146
Table 13.33: LSR Snapshot 147
Table 13.34: LSR financial performance ($m), 2003–07 148
Table 13.35: Omnicare Snapshot 149
xii
Table 13.37: SGS Snapshot 151
Table 13.38: SGS financial performance ($m), 2003–07 152
Table 13.39: CMIC Snapshot 153
Table 13.40: CMIC financial performance ($m), 2005–08 154
Table 13.41: WuXi Pharmatech Snapshot 155
Table 13.42: WuXi Pharmatech financial performance ($m), 2003–07 156
Table 13.43: BioFocus Snapshot 157
Table 13.44: BioFocus financial performance ($m), 2005–07 158
Table 13.45: LAB Research Snapshot 159
Table 13.46: LAB Research financial performance ($m), 2005–07 160
Table 13.47: UBC Snapshot 161
Table 13.48: Bio-Imaging Snapshot 162
